Sig Brokerage LP Acquires New Shares in Pfizer Inc. (NYSE:PFE)

Sig Brokerage LP purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 41,553 shares of the biopharmaceutical company's stock, valued at approximately $1,102,000.

Several other institutional investors also recently modified their holdings of PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer during the fourth quarter valued at $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new position in Pfizer in the 4th quarter worth about $27,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the fourth quarter valued at approximately $28,000. Finally, Noble Wealth Management PBC purchased a new position in Pfizer in the fourth quarter worth $31,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.23 on Friday, hitting $22.83. 37,727,922 shares of the company were exchanged, compared to its average volume of 40,925,832. The stock's 50 day moving average price is $23.65 and its 200 day moving average price is $25.34. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $129.77 billion, a P/E ratio of 16.19, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.82 earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.54%. Pfizer's dividend payout ratio is presently 124.64%.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.